Pediatric Histoplasmosis Medication

  • Author: James S Hagood, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Apr 23, 2012
 

Medication Summary

Always consult the latest information regarding the drugs of choice (DOCs), the dosages, and the routes of administration. Consultation with infectious diseases specialists can be helpful in choosing appropriate therapy.

Next

Antifungal agents

Class Summary

Systemic antifungal treatment is indicated for severe acute pulmonary histoplasmosis, chronic pulmonary histoplasmosis (CPH), progressive disseminated histoplasmosis (PDH), and any manifestation in an immunocompromised patient (see Treatment).

Amphotericin B is the mainstay of therapy for most systemic fungal infections. It is highly effective but has potential adverse effects. New lipid formulations of amphotericin B reduce renal toxicity; however, they are expensive and their improvements in efficacy are not proven. A double-blind randomized trial performed to compare liposomal amphotericin B (L-AMB) with the standard formulation (AmB) in patients with AIDS showed that L-AMB was at least as effective as AmB, with marked reduction in renal toxicity.[17]

Echinocandins (eg, caspofungin) should not be used.

View full drug information

Amphotericin B (Amphocin, Fungizone)

 

Produced by strain of Streptomyces nodosus. Fungistatic or fungicidal. Binds to sterols (eg, ergosterol) in fungal cell membrane, causing intracellular components to leak, with subsequent fungal cell death. DOC for severe or disseminated histoplasmosis.

Previous
Next

Antifungal agents, azoles

Class Summary

The azole antifungal agents are divided into 2 groups: imidazoles and triazoles. The imidazoles are an older group and include miconazole, ketoconazole, and clotrimazole. The triazoles consist of fluconazole; itraconazole; and the new second-generation azoles ravuconazole (investigational in the United States), voriconazole, and posaconazole.

Itraconazole is more effective than ketoconazole or fluconazole for treatment of histoplasmosis. It is also effective for long-term suppression of histoplasmosis in patients with AIDS.

Voriconazole and posaconazole may be useful in patients who are intolerant of or who fail treatment with AmB or itraconazole. In vitro studies with voriconazole and posaconazole have shown the activity of these agents against H capsulatum, Blastomyces dermatitidis, and Coccidioides immitis. Data from a few animal studies have verified their efficacy in vivo.[18, 19]

Posaconazole is reported to be effective for histoplasmosis in a small number of patients. In a case series, 6 of 7 patients were successfully treated with posaconazole.[20] Four of these 6 patients had disseminated infection, and, in all, other therapy failed or was intolerable.

Phase 3 clinical trials for the treatment of invasive fungal infections have been completed, and the US Food and Drug Administration recently approved posaconazole for the prophylaxis of invasive Aspergillus and Candida infections in high-risk, severely immunocompromised patients aged 13 years or older.

View full drug information

Itraconazole (Sporanox)

 

Synthetic triazole antifungal agent. Can be used in CPH, but relapse rate higher than with amphotericin B.

View full drug information

Ketoconazole (Nizoral)

 

Synthetic imidazole antifungal agent. Can be used for CPH, but relapse rate higher than that of amphotericin B.

View full drug information

Fluconazole (Diflucan)

 

Synthetic triazole antifungal with low plasma protein binding. CNS penetration better than that of imidazoles.

View full drug information

Posaconazole (Noxafil)

 

Triazole antifungal agent. Blocks ergosterol synthesis by inhibiting lanosterol 14-alpha-demethylase and the accumulation of sterol precursors. Action disrupts cell membrane. Available as PO susp 200 mg/5 mL. Indicated for prophylaxis of invasive Aspergillus and Candida infections in patients at high risk because of severe immunosuppression.

Previous
Next

NSAIDs

Class Summary

NSAIDs have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may include inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions. A brief course of NSAIDs may be required for patients who develop rheumatologic symptoms.

View full drug information

Naproxen (Aleve, Naprosyn)

 

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

View full drug information

Ibuprofen (Motrin, Advil, Ibuprin)

 

Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

James S Hagood, MD  Professor of Pediatrics and Chief, Division of Respiratory Medicine, Department of Pediatrics, University of California, San Diego, School of Medicine and Rady Children's Hospital of San Diego

James S Hagood, MD is a member of the following medical societies: American Thoracic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Asad Ansari, MD, MPH  Attending Physician, Pediatric Pulmonology and Infectious Diseases, Memorial Children's Hospital, South Bend, Indiana

Asad Ansari, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Gulnur Com, MD  Pediatric Pulmonologist, University of Arkansas for Medical Sciences Children's Hospital

Gulnur Com, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, and Cystic Fibrosis Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Glenn Fennelly, MD, MPH  Director, Division of Infectious Diseases, Lewis M Fraad Department of Pediatrics, Jacobi Medical Center; Clinical Associate Professor of Pediatrics, Albert Einstein College of Medicine

Glenn Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD  Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Mary E Cataletto, MD  Director of Children's Sleep Services, Winthrop Sleep Disorders Center; Professor of Clinical Pediatrics, State University of New York at Stony Brook

Mary E Cataletto, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Chest Physicians

Disclosure: Shering Plough Pharmaceuticals Honoraria Consulting

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

References

  1. Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. Mar 2010;10(3):687-91. [Medline].

  2. Chamany S, Mirza SA, Fleming JW, Howell JF, Lenhart SW, Mortimer VD, et al. A large histoplasmosis outbreak among high school students in Indiana, 2001. Pediatr Infect Dis J. Oct 2004;23(10):909-14. [Medline].

  3. McKinsey DS, McKinsey JP. Pulmonary histoplasmosis. Semin Respir Crit Care Med. Dec 2011;32(6):735-44. [Medline].

  4. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am. Mar 2003;17(1):1-19, vii. [Medline].

  5. Rosenthal J, Brandt KD, Wheat LJ, Slama TG. Rheumatologic manifestations of histoplasmosis in the recent Indianapolis epidemic. Arthritis Rheum. Sep 1983;26(9):1065-70. [Medline].

  6. AETC. Clinical Manual for Management of the HIV-Infected Adult. AETC National Resource Center [serial online]. Available at http://www.aids-ed.org/aetc?page=cm-515_histoplasmosis. Accessed January 11, 2007.

  7. Mandell GL, Bennett JE, Dolin R. Histoplasmosis. In: Principles and Practice of Infectious Diseases. 6th ed. Oxford, England: Churchill Livingstone; 2004.

  8. Cionni DA, Lewis SA, Petersen MR, Foster RE, Riemann CD, Sisk RA, et al. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. Ophthalmology. Feb 2012;119(2):327-32. [Medline].

  9. Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis. Mar 15 2005;40(6):844-52. [Medline].

  10. Rangel-Castilla L, Hwang SW, White AC, Zhang YJ. Neuroendoscopic Diagnosis of Central Nervous System Histoplasmosis with Basilar Arachnoiditis. World Neurosurg. Nov 7 2011;[Medline].

  11. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis. Sep 2006;8(3):128-39. [Medline].

  12. Swartzentruber S, LeMonte A, Witt J, Fuller D, Davis T, Hage C, et al. Improved detection of Histoplasma antigenemia following dissociation of immune complexes. Clin Vaccine Immunol. Mar 2009;16(3):320-2. [Medline].

  13. Wheat LJ, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. Diagn Microbiol Infect Dis. May 2002;43(1):29-37. [Medline].

  14. O'Shaughnessy EM, Shea YM, Witebsky FG. Laboratory diagnosis of invasive mycoses. Infect Dis Clin North Am. Mar 2003;17(1):135-58. [Medline].

  15. Maubon D, Simon S, Aznar C. Histoplasmosis diagnosis using a polymerase chain reaction method. Application on human samples in French Guiana, South America. Diagn Microbiol Infect Dis. May 15 2007;[Medline].

  16. Adderson EE. Histoplasmosis in a pediatric oncology center. J Pediatr. Jan 2004;144(1):100-6. [Medline].

  17. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. Jul 16 2002;137(2):105-9. [Medline]. [Full Text].

  18. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. Oct 2005;56(4):745-55. [Medline].

  19. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. Jun 15 2006;42(12):1726-34. [Medline].

  20. Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. Apr 2007;54(4):319-27. [Medline].

  21. Antachopoulos C, Walsh TJ. New agents for invasive mycoses in children. Curr Opin Pediatr. Feb 2005;17(1):78-87. [Medline].

  22. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. Apr 1969;99(4):Suppl:1-132. [Medline].

  23. George R, Penn R. Histoplasmosis. In: Sarosi GA, Davies SF, eds. Fungal Diseases of the Lung. New York, NY: Raven; 1993:39-50.

  24. Guimaraes AJ, Pizzini CV, De Matos Guedes HL, et al. ELISA for early diagnosis of histoplasmosis. J Med Microbiol. Jun 2004;53(Pt 6):509-14. [Medline].

  25. Hamilton AJ. Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Med Mycol. Dec 1998;36(6):351-64. [Medline].

  26. Joseph Wheat L. Current diagnosis of histoplasmosis. Trends Microbiol. Oct 2003;11(10):488-94. [Medline].

  27. Keating GM. Posaconazole. Drugs. 2005;65(11):1553-67. [Medline].

  28. Kumar N, Singh S, Govil S. Adrenal histoplasmosis: clinical presentation and imaging features in nine cases. Abdom Imaging. Sep-Oct 2003;28(5):703-8. [Medline].

  29. Kurowski R, Ostapchuk M. Overview of histoplasmosis. Am Fam Physician. Dec 15 2002;66(12):2247-52. [Medline].

  30. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis. Mar 1992;14 Suppl 1:S37-42. [Medline].

  31. Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg. Dec 1992;54(6):1053-7; discussion 1057-8. [Medline].

  32. Mocherla S, Wheat LJ. Treatment of histoplasmosis. Semin Respir Infect. Jun 2001;16(2):141-8. [Medline].

  33. Murray JF, Nadel JA. Histoplasmosis. In: Textbook of Respiratory Medicine. 4th ed. 2005:1045-55.

  34. Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore). Sep 1997;76(5):339-54. [Medline].

  35. [Guideline] Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis. Apr 2000;30(4):688-95. [Medline].

  36. Wiedermann BL. Histoplasmosis. In: Feigin RD, Cherry JD, Fletcher J, eds. Textbook of Pediatric Infectious Diseases. WB Saunders; 1998:2337-50.

 
Previous
Next
 
Hilar lymphadenopathy in an 11-year-old child.
Map demonstrates the distribution of histoplasmin skin-test positivity by region. Used with permission from the American Thoracic Society.
Hematoxylin and eosin stain of infected lung tissue. Histoplasma organisms appear to have a false capsule.
Starling roost in Alabama.
Acute pulmonary syndrome in a 16-year-old female adolescent.
Fibrosing mediastinitis with mediastinal widening and tracheal deviation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.